Video
Dr. Vaishampayan on FGFR inhibitors and genetic testing in bladder cancer
Author(s):
Video Player is loading.
Ulka Nitin Vaishampayan, MBBS, discusses the FGFR inhibitor erdafitinib (Balversa) and the importance of genetic/genomic testing in bladder cancer.
Erdafitinib is approved by the FDA for the treatment of adult patients with locally advanced or metastatic bladder cancer with an FGFR3 or FGFR2 alteration that has progressed on platinum-containing chemotherapy. Vaishampayan stresses how it is crucial that patients with bladder cancer receive genetic testing to determine their eligibility for this treatment should they progress on first-line chemotherapy.
Vaishampayan is director, Phase I Program, Rogel Cancer Center, Michigan Medicine, and professor of Internal Medicine, University of Michigan.
Related Videos
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
Tim Richardson, MD, on genetic testing in the era of targeted therapies
Discussing germline testing for prostate cancer with veterans
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
Germline testing study’s implications for veteran access to prostate cancer treatments
Kara Cossis, PA-C, MPH, on challenges, opportunities with genetic testing
Daniel Kwon, MD, on germline testing for prostate cancer in veterans with service-connected benefits
Related Content
